SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC
IPIC 0.00010000.0%Dec 18 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: (no name provided) who wrote (658)9/17/1997 2:51:00 PM
From: Thomas C. White   of 1359
 
I suspect that most of any case against AHP/IPIC would revolve around claims that AHP marketed the drugs too aggressively, perhaps implied that doctors could use drug combinations to enhance performance etc. It would be difficult to prove that the trials should have shown negative effects since they followed FDA procedures and these things did not seem to show up. It probably does not matter whether IPIC received license fees from AHP from a tort standpoint, as this does not affect the issue of any negligence on the part of IPIC.

In court it's also much easier to bash a gigantic drug company as compared with a small biotech.

This is basically the reason why AHP has lost several billion dollars in market capitalization over this issue whereas IPIC has lost much less.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News